Autopsy report · NCT04902911
Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold)
Cause of deathFutility, also regulatory or ethics
“Failed to meet FDA criteria on one target at FDA, CDC, and market is not looking for rapid antibody tests.”
Life of this trial
- Registered 1 month after it had already started.
- Ran for about 1 year 4 months before it stopped.
- 91 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Sponsor
- Medical College of Wisconsin
- Sponsor type
- University, hospital or other
- Conditions
- Covid19
- Interventions
- COVID-19 SARS-CoV IgG/IgM antibody rapid test
- Participants
- 91
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group
“FDA request as study could not serve as the confirmatory trial.” - Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More
“Feasibility of the clinical trial could not be confirmed at the different sites.” - Exploring the Impact of Two-week Kava on the Metabolism of Nicotine and NNK
“Terms could not be met with the FDA.” - Iontophoresis in Psoriasis
“FDA did not provide approval of the use of the drug for the study” - Topical Cannabidiol Cream and Post-exercise Recovery
“The researchers were not able to acquire funding to initiate the study. Also, the study was not approved by the local IRB which requested a FDA new drug application.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.